CO2023001953A2 - Compuestos fosfolípidos y usos de los mismos - Google Patents

Compuestos fosfolípidos y usos de los mismos

Info

Publication number
CO2023001953A2
CO2023001953A2 CONC2023/0001953A CO2023001953A CO2023001953A2 CO 2023001953 A2 CO2023001953 A2 CO 2023001953A2 CO 2023001953 A CO2023001953 A CO 2023001953A CO 2023001953 A2 CO2023001953 A2 CO 2023001953A2
Authority
CO
Colombia
Prior art keywords
compounds
phospholipid compounds
phospholipid
alone
treatment
Prior art date
Application number
CONC2023/0001953A
Other languages
English (en)
Inventor
Devan Naduthambi
Jonathan William Medley
Peiyuan Wang
Scott E Lazerwith
Philip A Morganelli
Thomas P Stratton
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CO2023001953A2 publication Critical patent/CO2023001953A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Abstract

Se describen compuestos y métodos para usar dichos compuestos, solos o en combinación con agentes adicionales, y composiciones farmacéuticas de dichos compuestos para el tratamiento de infecciones virales.
CONC2023/0001953A 2020-08-24 2023-02-22 Compuestos fosfolípidos y usos de los mismos CO2023001953A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063069449P 2020-08-24 2020-08-24
US202063092386P 2020-10-15 2020-10-15
US202163151509P 2021-02-19 2021-02-19
PCT/US2021/047145 WO2022046631A1 (en) 2020-08-24 2021-08-23 Phospholipid compounds and uses thereof

Publications (1)

Publication Number Publication Date
CO2023001953A2 true CO2023001953A2 (es) 2023-03-17

Family

ID=77802251

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0001953A CO2023001953A2 (es) 2020-08-24 2023-02-22 Compuestos fosfolípidos y usos de los mismos

Country Status (16)

Country Link
US (3) US11773122B2 (es)
EP (1) EP4200301A1 (es)
JP (1) JP2023538442A (es)
KR (1) KR20230057419A (es)
CN (1) CN116323630A (es)
AU (2) AU2021330835B2 (es)
BR (1) BR112023002951A2 (es)
CA (1) CA3188373A1 (es)
CL (1) CL2023000524A1 (es)
CO (1) CO2023001953A2 (es)
CR (1) CR20230100A (es)
DO (1) DOP2023000037A (es)
IL (1) IL300412A (es)
MX (1) MX2023002233A (es)
TW (2) TW202337471A (es)
WO (1) WO2022046631A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116323630A (zh) 2020-08-24 2023-06-23 吉利德科学公司 磷脂化合物及其用途
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
WO2022265964A1 (en) 2021-06-14 2022-12-22 VenatoRx Pharmaceuticals, Inc. Orally-bioavailable nucleoside analogs
WO2023023527A1 (en) * 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN115251042B (zh) * 2022-09-08 2023-06-02 安徽科技学院 一种家禽精液稀释缓冲液及其制备和家禽精液冷存方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
EP0262876B1 (en) 1986-09-27 1992-04-29 Toyo Jozo Kabushiki Kaisha Nucleoside-phospholipid conjugate
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
RU2258707C2 (ru) 1999-12-03 2005-08-20 Де Риджентс ов де Юниверсити ов Калифорния, Сан-Диего Фосфонатные соединения
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
MXPA02011641A (es) 2000-05-26 2004-07-30 Idenix Cayman Ltd Metodos para tatar infecciones por viurs de hepatitis delta con beta-l-2'-desoxi-nucleosidos.
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
BRPI0411900B8 (pt) 2003-06-26 2021-05-25 Biotron Ltd compostos e composições farmacêuticas compreendendo os mesmos
US8101745B2 (en) 2004-12-16 2012-01-24 The Regents Of The University Of California Lung-targeted drugs
US20090156545A1 (en) 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
ZA200800256B (en) 2005-06-24 2009-08-26 Biotron Ltd Antiviral compounds and methods
US20100254942A1 (en) 2007-08-03 2010-10-07 Biotron Limited Hepatitis c antiviral compositions and methods
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
AU2009298802A1 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
EP2826369A3 (en) 2008-11-06 2015-03-18 Vascular Biogenics Ltd. Oxidized lipid compounds and uses thereof
EP2500345B1 (en) 2009-11-11 2015-01-28 Sumitomo Dainippon Pharma Co., Ltd. 8-azabicyclo[3.2.1]octane-8-carboxamide derivative
WO2011100131A2 (en) 2010-01-28 2011-08-18 Alnylam Pharmacuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
EP2794627B1 (en) 2011-12-22 2018-09-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EA201590384A1 (ru) 2012-09-10 2015-10-30 Ф. Хоффманн-Ля Рош Аг 6-аминокислота-гетероарилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в
KR102327888B1 (ko) 2012-12-21 2021-11-17 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
WO2014143643A1 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California, A California Corporation Acyclic nucleoside phosphonate diesters
CA2913206C (en) 2013-06-26 2022-08-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
KR101949251B1 (ko) 2013-09-11 2019-02-18 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) B형간염바이러스 감염의 치료 방법 및 치료용 약학적 조성물
CN105829333A (zh) 2013-10-11 2016-08-03 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
EP3099685B1 (en) 2014-01-30 2018-04-18 F.Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
EA030115B9 (ru) 2014-03-07 2018-09-28 Ф. Хоффманн-Ля Рош Аг Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
MX2016014728A (es) 2014-05-13 2017-03-23 Hoffmann La Roche Dihidroquinolizidinonas novedosas para el tratamiento y profilaxis de la infeccion con virus de la hepatitis b.
CN106573011A (zh) 2014-06-24 2017-04-19 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物
EP3160475B1 (en) 2014-06-24 2024-01-03 Janssen Pharmaceuticals, Inc. Substituted nucleosides and nucleotides to treat filoviridae infections
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
MX2017001862A (es) 2014-08-14 2017-05-15 Hoffmann La Roche Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
WO2016102438A1 (en) 2014-12-23 2016-06-30 F. Hoffmann-La Roche Ag Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
JP6506845B2 (ja) 2014-12-30 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の治療及び予防のための新規テトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類
JP2018504891A (ja) 2014-12-31 2018-02-22 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ リアルタイムＰＣＲによる細胞溶解物からのＨＢＶ ｃｃｃＤＮＡ定量化のための新規ハイスループット法
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
WO2016120186A1 (en) 2015-01-27 2016-08-04 F. Hoffmann-La Roche Ag Recombinant hbv cccdna, the method to generate thereof and the use thereof
EP3256471B1 (en) 2015-02-11 2018-12-12 F. Hoffmann-La Roche AG Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
US11963972B2 (en) 2016-03-23 2024-04-23 Emory University Antiviral agents and nucleoside analogs for treatment of Zika virus
BR112019016316A2 (pt) 2017-02-08 2020-03-31 Biotron Limited Métodos para o tratamento da influenza
TW201836615A (zh) * 2017-03-14 2018-10-16 美商基利科學股份有限公司 治療貓冠狀病毒感染之方法
US11306111B2 (en) 2017-07-31 2022-04-19 January Therapeutics, Inc. Organophosphate derivatives
EP3684782A1 (en) 2017-09-18 2020-07-29 Janssen BioPharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN111971284A (zh) 2017-12-27 2020-11-20 埃默里大学 核苷和/或nadph氧化酶(nox)抑制剂作为髓样特异性抗病毒剂的联合模式
CA3092834A1 (en) 2018-03-02 2019-09-06 January Therapeutics, Inc. Nanoparticle compositions
TWI791193B (zh) * 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
US20230287029A1 (en) 2020-07-24 2023-09-14 The Regents Of The University Of California Antiviral prodrugs, pharmaceutical formulations, and methods
CN116323630A (zh) 2020-08-24 2023-06-23 吉利德科学公司 磷脂化合物及其用途
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
WO2022265964A1 (en) 2021-06-14 2022-12-22 VenatoRx Pharmaceuticals, Inc. Orally-bioavailable nucleoside analogs
WO2023023527A1 (en) * 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Also Published As

Publication number Publication date
US20230250117A1 (en) 2023-08-10
DOP2023000037A (es) 2023-07-09
TW202222323A (zh) 2022-06-16
AU2021330835A1 (en) 2023-03-30
JP2023538442A (ja) 2023-09-07
KR20230057419A (ko) 2023-04-28
CR20230100A (es) 2023-04-28
BR112023002951A2 (pt) 2023-03-21
WO2022046631A1 (en) 2022-03-03
AU2021330835B2 (en) 2023-12-14
CL2023000524A1 (es) 2023-09-29
AU2024201573A1 (en) 2024-04-04
US20220081455A1 (en) 2022-03-17
TW202337471A (zh) 2023-10-01
CN116323630A (zh) 2023-06-23
TWI807399B (zh) 2023-07-01
EP4200301A1 (en) 2023-06-28
IL300412A (en) 2023-04-01
US20240025932A1 (en) 2024-01-25
US11773122B2 (en) 2023-10-03
MX2023002233A (es) 2023-03-15
CA3188373A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
CL2023000555A1 (es) Compuestos y métodos para el tratamiento de infecciones virales
CO2023001953A2 (es) Compuestos fosfolípidos y usos de los mismos
DOP2022000293A (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
CL2023001949A1 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso (divisional de solicitud de patente no. 3422-2020)
CL2022003510A1 (es) Inhibidores de cisteína proteasas y sus métodos de uso
CL2022001719A1 (es) Compuestos moduladores de la diacilglicerol quinasa
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
CO2023004594A2 (es) Compuestos fosfolípidos y usos de estos
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
CO2021010150A2 (es) Inhibidores irreversibles de la interacción menina-mll
CO2018013077A2 (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CO2018009559A2 (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.
CU20210008A7 (es) Aspirasas solubilizadas
CO2023013321A2 (es) Compuestos de oxoisoindolina sustituidos con piridinilo